Depressive DisordersPTSDSuicidalityKetamine

Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample

This observational study (n=202, 470, and 624) compares ketamine alone (KET) to ketamine combined with psychotherapy (KET+PSY) (35mg x 6) for depression and PTSD. Both treatments led to substantial symptom improvements, but no significant differences were found between groups. Exploratory analyses suggest younger females may benefit more from combined treatment, while older males may do better with ketamine alone.

Authors

  • Moore, T. M.
  • Walker, K.
  • Tung, E.

Published

Journal of Affective Disorders
individual Study

Abstract

Depression and PTSD are prevalent psychiatric conditions that often co-occur and significantly impact quality of life. Ketamine has emerged as a promising rapid-acting treatment for both conditions, while traditional treatments like psychotherapy typically require weeks to show effects. This study investigated whether combining ketamine with psychotherapy produces greater symptom improvement compared to ketamine alone. We analyzed overlapping samples of N = 202, N = 470, and N = 624 help-seeking individuals (all samples ∼60 % female, mean age ∼ 42 years) who received either ketamine alone (KET) or ketamine plus psychotherapy (KET+PSY) across 4-14 treatment sessions within a 30- or 180-day period. Depression symptoms were measured using the PHQ-9, and PTSD symptoms were assessed using the PCL-5. Trajectories of symptom change were analyzed using generalized additive mixed-effects models, controlling for baseline symptoms, demographics, and treatment intervals. Both treatment groups showed substantial improvement in depression and PTSD symptoms, with similar patterns of rapid initial decline followed by stabilization. Contrary to our hypothesis, we found no significant differences in symptom trajectories between the KET and KET+PSY groups. Exploratory analyses revealed non-significant but notable patterns where younger females showed better outcomes with combined treatment, while older males showed better outcomes with ketamine alone. These findings suggest that ketamine's therapeutic effects may be robust enough that additional psychotherapy during the acute treatment phase does not significantly enhance 30-day (and possibly 180-day) outcomes. However, longer-term benefits of combined treatment and potential demographic-specific treatment responses warrant further investigation. These results have important implications for treatment planning and resource allocation in clinical settings.

Available with Blossom Pro

Research Summary of 'Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample'

Introduction

Depression and post-traumatic stress disorder (PTSD) are common, often co-occurring conditions that produce substantial functional impairment and elevated suicide risk. Ketamine has emerged as a rapid-acting intervention for both disorders through NMDA receptor antagonism, downstream increases in glutamate and AMPA throughput, and promotion of neuroplasticity (for example via BDNF and mTORC1 pathways). These neurobiological effects can produce quick symptom relief and transient synaptogenesis, distinguishing ketamine from conventional antidepressants that typically require weeks to act. Despite growing interest in ketamine-assisted psychotherapy (KAP), evidence remains mixed and methodologically heterogeneous. Prior studies and reviews have suggested potential additive or synergistic effects when psychotherapy is combined with ketamine, but many investigations lack direct comparisons against ketamine-only treatment, vary in dosing and psychotherapy modality, and are insufficiently powered to demonstrate synergy. Moore and colleagues designed the present study to test whether combining ketamine with psychotherapy produces greater reductions in depression and PTSD symptoms than ketamine alone during the acute treatment phase. Their stated hypothesis was that combined treatment would yield faster symptom decline and/or a lower symptom plateau across six ketamine administrations compared with ketamine without concurrent psychotherapy.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

  • Study Type
    individual
  • Journal
  • Compound
  • Topics
  • APA Citation

    Moore, T. M., Walker, K., Tung, E., Teed, A. R., Hell, F., Kinreich, S., Jung, R., Abdel, F., Hanson, R. W., & Ahmed, S. S. (2025). Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. Journal of Affective Disorders, 381, 233-241. https://doi.org/10.1016/j.jad.2025.04.041

References (3)

Papers cited by this study that are also in Blossom

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, P. J., Morris, P. J. et al. · Nature (2016)

Convergent Mechanisms Underlying Rapid Antidepressant Action

Zanos, P., Thompson, S. M., Duman, R. S. et al. · CNS Drugs (2018)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.